Haleon (HLN) Return on Capital Employed (2023)

Haleon (HLN) posted Return on Capital Employed of 14.35% for Q4 2023.

Haleon (HLN) Return on Capital Employed (2023) Analysis & Trends

Haleon's Return on Capital Employed history runs 1 years deep, the most recent figure standing at 14.35% for Q4 2023.

Quarterly Return on Capital Employed changed N/A year-over-year to 14.35% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 14.35% (changed N/A YoY) and the FY2025 annual result came in at 8.61%, up 71.0% from the prior year.
Return on Capital Employed was 14.35% for Q4 2023 at Haleon.
Across five years, Return on Capital Employed topped out at 14.35% in Q4 2023 and bottomed at 14.35% in Q4 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Haleon	88.07 Bn	86.20 Bn	-	-
2	Teva Pharmaceutical Industries	35.75 Bn	32.01 Bn	1.97 Bn	8.52%
3	Zoetis	31.84 Bn	29.90 Bn	1.62 Bn	27.36%
4	Takeda Pharmaceutical	27.18 Bn	23.12 Bn	4.39 Bn	-1.50%
5	United Therapeutics	23.09 Bn	20.93 Bn	648.10 Mn	21.43%
6	RedHill Biopharma	21.32 Bn	21.32 Bn	-	-
7	Viatris	19.96 Bn	18.16 Bn	1.16 Bn	0.46%
8	Neurocrine Biosciences	17.66 Bn	16.34 Bn	800.70 Mn	20.04%
9	Elanco Animal Health	12.44 Bn	12.02 Bn	785.00 Mn	5.24%
10	Vireo Growth	10.53 Bn	10.38 Bn	59.30 Mn	0.91%

Historic Data

Download Data

Date	Value
Dec 31, 2023	14.35%